Sanofi (SNY)
(Delayed Data from NSDQ)
$51.20 USD
+0.77 (1.53%)
Updated Jul 24, 2024 04:00 PM ET
Pre-Market: $52.70 +1.50 (2.93%) 9:02 AM ET
3-Hold of 5 3
B Value D Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$51.20 USD
+0.77 (1.53%)
Updated Jul 24, 2024 04:00 PM ET
Pre-Market: $52.70 +1.50 (2.93%) 9:02 AM ET
3-Hold of 5 3
B Value D Growth C Momentum C VGM
Zacks News
Is ASLAN Pharmaceuticals (ASLN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how ASLAN Pharmaceuticals Ltd. (ASLN) and Sanofi (SNY) have performed compared to their sector so far this year.
Markets Continue Steady Slide; META, EBAY Beat Q1 Earnings
by Mark Vickery
Except the Nasdaq, which snapped a two-day losing streak and was the only major index in the green all day.
Roche (RHHBY) Q1 Revenues Decline on Lower COVID-19 Test Sales
by Zacks Equity Research
Roche's (RHHBY) performance in first-quarter 2023 is pretty ho-hum as COVID-19-test sales continue to decline.
Is a Surprise Coming for Sanofi (SNY) This Earnings Season?
by Zacks Equity Research
Sanofi (SNY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Novartis (NVS) Tops on Q1 Earnings & Revenues, Ups View
by Zacks Equity Research
Novartis (NVS) beats on earnings and sales in the first quarter, and raises its annual guidance on strong momentum.
AstraZeneca (AZN) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Higher sales of AstraZeneca's (AZN) key medicines, Lynparza, Tagrisso, Imfinzi and Farxiga are expected to have driven sales, partially offset by lower sales of legacy drugs.
Bristol-Myers (BMY) to Report Q1 Earnings: What+'s in Store?
by Zacks Equity Research
Investors are likely to focus on the demand for Eliquis and Opdivo along with an incremental contribution from newer drugs when Bristol-Myers (BMY) reports Q1 results.
Eli Lilly (LLY) to Report Q1 Earnings: Will It Beat Estimates?
by Zacks Equity Research
Higher demand for its key drugs is likely to have offset generic competition for several drugs and may have boosted Lilly's (LLY) first-quarter sales.
4 Pharma, Biotech Stocks Poised to Beat Q1 Earnings Estimates
by Ekta Bagri
We look at a few pharma/biotech companies, SNY, AMGN, REGN, ACAD, which are poised to beat on earnings in the first quarter.
Will HIV and Oncology Propel Gilead's (GILD) Q1 Earnings?
by Zacks Equity Research
Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its first-quarter 2023 results.
Sanofi (SNY) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Sanofi (SNY) have what it takes to be a top stock pick for momentum investors? Let's find out.
Merck (MRK) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda when the company reports Q1 earnings.
Sanofi (SNY) Stock Moves -0.45%: What You Should Know
by Zacks Equity Research
In the latest trading session, Sanofi (SNY) closed at $55.47, marking a -0.45% move from the previous day.
Zacks.com featured highlights include Unum, Graphic Packaging Holding, AutoNation and Sanofi
by Zacks Equity Research
Unum, Graphic Packaging Holding, AutoNation and Sanofi are part of the Zacks Screen of the Week article.
Will Sanofi (SNY) Surpass Estimates This Earnings Season?
by Zacks Equity Research
Sanofi's (SNY) top line is likely to have been driven by higher sales of Dupixent.
Zacks.com featured highlights include Unum Group, Sanofi, KB Home, PVH and Telefonica Brasil
by Zacks Equity Research
Unum Group, Sanofi, KB Home, PVH and Telefonica Brasil are part of the Zacks Screen of the Week article.
4 Stocks Trading Near 52-Week High That Can Scale Higher
by Vasundhara Sawalka
Investors target stocks that have been on a bullish run lately. Stocks like UNM, GPK, SNY and AN that are seeing price strength have a high chance of carrying the momentum forward.
Nektar (NKTR) Starts New Restructuring Plan to Curb Cash Burn
by Zacks Equity Research
The new restructuring plan will allow Nektar (NKTR) to extend its cash runway into mid-2026. The company plans to reduce its workforce by approximately 60%.
FDA Expands AbbVie's (ABBV) Qulipta Label in Chronic Migraine
by Zacks Equity Research
Following FDA's label-expansion approval, AbbVie's (ABBV) Qulipta is the first and the only oral CGRP receptor antagonist approved to prevent episodic and chronic migraines.
J&J (JNJ) Q1 Earnings & Sales Top, 2023 View Up, Stock Rises
by Zacks Equity Research
J&J (JNJ) beats estimates for first-quarter earnings and sales. It raises full-year sales and earnings guidance.
Zacks.com featured highlights include Sanofi, Medallion Financial, Plains All American Pipeline and KB Home
by Zacks Equity Research
Sanofi, Medallion Financial, Plains All American Pipeline and KB Home are part of the Zacks Screen of the Week article.
Pick These 5 Bargain Stocks With Amazingly Low EV/EBITDA Ratios
by Anindya Barman
We have screened bargain stocks UNM, SNY, KBH, PVH and VIV based on the EV-to-EBITDA ratio, which offers a clearer picture of valuation and earnings potential.
3 Reasons Growth Investors Will Love Sanofi (SNY)
by Zacks Equity Research
Sanofi (SNY) possesses solid growth attributes, which could help it handily outperform the market.
SNY vs. LLY: Which Stock Is the Better Value Option?
by Zacks Equity Research
SNY vs. LLY: Which Stock Is the Better Value Option?
Is Innoviva (INVA) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.